Sermonix Pharmaceuticals

Sermonix Pharmaceuticals

Pharmaceuticals, 3000 E Main St, Columbus, Ohio, 43209, United States, 11-50 Employees

sermonixpharma.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 61********

Who is SERMONIX PHARMACEUTICALS

Sermonix Pharmaceuticals, founded by David Portman, MDa leading clinical researcher and expert in womens healthfocuses on developing targeted therapeutics to treat ESR1-mutated metastatic...

Read More

map
  • 3000 E Main St, Columbus, Ohio, 43209, United States Headquarters: 3000 E Main St, Columbus, Ohio, 43209, United States
  • 2014 Date Founded: 2014
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 2833 | NAICS Code: 325412 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from SERMONIX PHARMACEUTICALS

Sermonix Pharmaceuticals Org Chart and Mapping

Employees

Elizabeth Attias

Chief Strategy and Business Development Officer

Gina Boruta

Clinical Project Manager

Noah Portman

Data Analysis Associate

Miriam Portman

Chief Operating Officer

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Sermonix Pharmaceuticals

Answer: Sermonix Pharmaceuticals's headquarters are located at 3000 E Main St, Columbus, Ohio, 43209, United States

Answer: Sermonix Pharmaceuticals's phone number is 61********

Answer: Sermonix Pharmaceuticals's official website is https://sermonixpharma.com

Answer: Sermonix Pharmaceuticals's revenue is $1 Million to $5 Million

Answer: Sermonix Pharmaceuticals's SIC: 2833

Answer: Sermonix Pharmaceuticals's NAICS: 325412

Answer: Sermonix Pharmaceuticals has 11-50 employees

Answer: Sermonix Pharmaceuticals is in Pharmaceuticals

Answer: Sermonix Pharmaceuticals contact info: Phone number: 61******** Website: https://sermonixpharma.com

Answer: Sermonix Pharmaceuticals, founded by David Portman, MDa leading clinical researcher and expert in womens healthfocuses on developing targeted therapeutics to treat ESR1-mutated metastatic breast and gynecological cancers. Our ELAINE Studies are evaluating an investigational oral drug, lasofoxifene, a novel targeted endocrine agent, in women and men with locally advanced or metastatic estrogen receptor-positive/human epidermal growth factor 2-negative (ER+/HER2-) breast cancer harboring an ESR1 mutation(s).

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access